LQ-080

N/A

Report date: 2025/03/21 17:20:10

Base Information

Drug NameLQ-080
Drug Alias NameLQ080LQ-080
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionAnti-Tumor necrosis factor superfamily member 15Anti-Interleukin-23 subunit p19
TargetsTumor necrosis factor superfamily member 15Interleukin-23 subunit p19
Therapy Area/IndicationsInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsInflammatory Bowel Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A